eEF2K expression is associated with resistance to frontline chemotherapeutics such as doxorubicin and paclitaxel, and eEF2K knockdown in an in vivo orthotopic model of breast cancer suppresses the growth of established breast cancer tumors and sensitizes the tumors to these chemotherapeutics [16], indicating the role of eEF2K expression in patient survival and prognosis. This evidence concerns the gene EEF2K and breast cancer.